Related Experiment Video
Updated: May 6, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II
Hui-Sheng Chen1, Zi-Ai Zhao2, Xin-Yu Shen2
1Department of Neurology, General Hospital of Northern Theater Command, Shenyang, China. chszh@aliyun.com.
Abstract:
This phase II, randomized, double blinded, multi-center study aims to explore whether intravenous edaravone dexborneol (ED) could improve clinical outcomes in patients with anterior circulation stroke with successful endovascular reperfusion (ClinicalTrials.gov: NCT04667637). Eligible patients were randomly (1:1) assigned into ED, which received intravenous ED (37.5 mg, 2/day, for 12 days) or control group, which received placebo. The primary endpoint was favorable functional outcome (a modified Rankin Scale [mRS] of 0-2 at 90 days). Two hundred patients were enrolled, including 97 in ED group and 103 in control group. The proportion of patients with 90-day mRS (0-2) was 58.7% (54/92) in ED group and 52.1% (49/94) in control group (unadjusted odds ratio 1.37, [95% CI 0.76-2.44], P = 0.29). This work suggests that intravenous ED is safe, but do not statistically improve 90-day functional outcomes in patients with anterior circulation stroke with successful endovascular reperfusion.
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Acute Coronary Syndrome III: Diagnostic Studies
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology

